Fulgent Genetics, Inc. (FLGT)
|Net Income (ttm)||214.31M|
|Trading Day||May 7|
|Day's Range||73.19 - 77.40|
|52-Week Range||13.40 - 189.89|
More than 4,500% revenue growth gave Wall Street and shareholders something to cheer about.
FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of 10.02% and 13.35%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
FULGENT GENETIC (FLGT) closed the most recent trading day at $73.01, moving +1.61% from the previous trading session.
TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “company”), a technology company providing large-scale COVID-19 testing services and comprehensive testing s...
TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology company providing comprehensive testing solutions through its sc...
Good news for the U.S. has been bad news for shareholders.
COVID-19 testing and NGS-based testing solutions are expected to have contributed to Fulgent Genetics' (FLGT) Q1 earnings.
FULGENT GENETIC (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FULGENT GENETIC (FLGT) closed at $87.64 in the latest trading session, marking a +0.52% move from the prior day.
The genetic testing giant's journey resembles the path of past winners.
The government is going to invest heavily in COVID-19 research and tracking, and these companies are likely to benefit.
FULGENT GENETIC (FLGT) closed at $86.78 in the latest trading session, marking a -0.99% move from the prior day.
If you are screening the market for high-return investments, you may want to consider the three non-cyclical stocks listed below, as their earnings yields (as calculated via Joel Greenblatt (Trades, Por...
Less COVID-19 testing means less revenue for some companies.
He also gave clues that point to a few possible targets.
Growth last year was awesome, but there is something to be even more excited about.
TEMPLE CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions throug...
In the latest trading session, FULGENT GENETIC (FLGT) closed at $88.95, marking a +1.37% move from the previous day.
They've underperformed the S&P 500 in the past month, but these stocks show lots of potential over the long term.
Recent advances in computer technology have lit a fuse under the genomic sequencing industry. And here's what investors need to know now.
FULGENT GENETIC (FLGT) closed at $85.24 in the latest trading session, marking a -0.42% move from the prior day.
A rebounding economy is a good time to thaw out your risk capital and start buying some high-risk stocks with long-term potential. The post 8 High-Risk Stocks to Buy That Are Worth Taking A Chance On ap...
Industry trends could support massive gains for shareholders over the next 10 years.
Shareholders could be big winners if the demand for COVID-19 testing lingers.
Investors seeking a multi-year growth opportunity should watch out for these three stocks.
Is (FLGT) Outperforming Other Medical Stocks This Year?
Gene science will continue to drive the healthcare sector to new heights.
If you are following the crowd, you might miss these disruptive companies.
This coronavirus testing company has been booming, but is its hot streak about to end?
One group especially stands out.
Agreement leverages Fulgent's Next Generation Sequencing (“NGS”) capabilities for genomic sequencing to aid in ongoing research of SARS-CoV-2, the virus that causes COVID-19 Agreement leverages Fulgent'...
Despite tremendous growth, the stock is cheap based on at least one common Wall Street metric.
These two genetic testing companies have different approaches.
Is (FLGT) Outperforming Other Medical Stocks This Year?
Thanks to a blowout fourth quarter, a Los Angeles-area diagnostic and genetics company saw its shares soar to an all-time high. Fulgent Genetics Inc.(NASDAQ:FLGT) hit nearly $190 during the first week o...
Amkor Technology (AMKR), Daqo New Energy (DQ) and Fulgent Genetics (FLGT) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
FULGENT GENETIC (FLGT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
New COVID-19 tests catapulted this company to fame, but investors are worried about what happens next.
Investors loved the company's fourth-quarter update but are concerned the growth could stall.
Fulgent Genetics (FLGT) stock is on the rise in pre-market trading and we know exactly why investors are so happy with the company. The post FLGT Stock: 3 Reasons Why Fulgent Genetics Is Soaring Today a...
TEMPLE CITY, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions throug...
The genetic-testing company is firing on all cylinders.
FULGENT GENETIC (FLGT) delivered earnings and revenue surprises of 40.59% and 30.77%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Strong earnings sent both of these healthcare stocks higher after hours on Thursday.
Shares of Fulgent Genetics (NASDAQ:FLGT) moved higher by 24.0% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 15400.00% year over year to $6....
Fourth Quarter 2020 Results:
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States ... [Read more...]
Diagnostics & Research
|IPO Date |
Sep 29, 2016
|Stock Exchange |
|Ticker Symbol |
According to 4 analysts, the average rating for FLGT stock is "Buy." The 12-month stock price forecast is 89.00, which is an increase of 19.24% from the latest price.